Endorsements of the Solidarity Call to Action
Tetra Images
            
        
            ©
            Credits 
            
        
    Endorsements of the "Solidarity call to action to realize equitable global access to COVID-19 health technologies through pooling of knowledge, intellectual property and data” include WHO Member States and other supporting organizations engaged in COVID-19 health technology related access work.
The following WHO Member States have informed WHO and/or the Government of Costa Rica that they are joining the Solidarity Call to Action
- Argentina
 - Bangladesh
 - Barbados
 - Belgium
 - Belize
 - Bhutan
 - Bolivia
 - Brazil
 - Chile
 - Dominican Republic
 - Ecuador
 - Egypt
 - El Salvador
 - Guatemala
 - Honduras
 - Indonesia
 - Kenya
 - Lebanon
 - Luxembourg
 - Malaysia
 - Maldives
 - Mexico
 - Mongolia
 - Mozambique
 
- Norway
 - Oman
 - Pakistan
 - Palau
 - Panama
 - Paraguay
 - Peru
 - Portugal
 - Saint Vincent and Grenadines
 - South Africa
 - Spain
 - Sri Lanka
 - Sudan
 - The Netherlands
 - Timor-Leste
 - Tunisia
 - Turkmenistan
 - Uruguay
 - Zimbabwe
 
Intergovernmental Organizations
United Nations Agencies
- UNAIDS (view statement)
 - UNDP ( view statement)
 - Unitaid (view statement)
 
Other Intergovernmental Organizations
- South Centre (view statement)
 
Nongovernmental Organizations
- DNDi (view statement) (in official relations with WHO)
 - HAI (in official relations with WHO)
 - Health GAP
 - KEI (view statement) (in official relations with WHO)
 - MPP (view statement) (in official relations with WHO)
 - Open COVID Pledge (view statement)
 - UAEM
 
Notable Personalities
- Achal Prabhala, Fellow of the Shuttleworth Foundation and Coordinator of AccessIBSA
 - Gregg Alton, former Chief Patient Officer, Gilead Sciences
 - Jacques Dubochet, Nobel Prize in Chemistry 2017
 - Joseph Stiglitz, Professor at Columbia University and Nobel Memorial Prize in Economic Sciences 2001
 - Mariana Mazzucato, Professor and Director of the Institute for Innovation and Public Purpose (IIPP) at University College London (UCL)
 - Paul Fehlner, Co-founder and President/CEO of reVision Therapeutics, Chief Intellectual Property Officer at Axcella Health and former Global Head of IP for Novartis Pharma